Navigation Links
URL Pharma Launches Colcrys(R) Patient Assistance Program
Date:12/23/2009

PHILADELPHIA, Dec. 23 /PRNewswire/ -- URL Pharma, Inc. today announced the launch of the Colcrys® (colchicine, USP) Patient Assistance Program, an initiative that will allow patients with limited means to save on Colcrys prescriptions. This program reflects URL Pharma's ongoing commitment to helping ensure that all patients who rely on the company's medications are able to access them, regardless of economic status. Colcrys is indicated for the prevention and treatment of gout flares and for the treatment of Familial Mediterranean Fever (FMF).

"URL Pharma believes that patients should not be forced to sacrifice in order to afford their medication, especially in these difficult economic times," said Richard H. Roberts, MD, PhD, President, CEO and Chairman, URL Pharma. "The Colcrys Patient Assistance Program will help ensure that limited income is not a barrier to patients who need Colcrys."

The Colcrys Patient Assistance Program will allow eligible uninsured patients to secure a 90-day supply of Colcrys( )for a $15 co-payment. The program is administered through Rx Outreach, a service provided by Express Scripts Specialty Distribution Services (ESSDS). Patients or physician offices can learn more about eligibility requirements and secure applications online at www.rxoutreach.com or by phone at 1-800-769-3880. The phone line is staffed from 7:00 am - 5:30 pm CST Monday through Friday.

Patients and physicians can also access the Rx Outreach program by visiting www.rxassist.org, www.pparx.org or www.needymeds.org. Preferred or direct clinics may fax their orders to 1-888-430-9818.

Important Safety Information

Colcrys (colchicine, USP) tablets are indicated for the prophylaxis and treatment of acute gout flares and Familial Mediterranean Fever (FMF).

Colcrys is contraindicated in patients with renal or hepatic impairment who are concurrently prescribed P-gp inhibitors or strong inhibitors of CYP3A4 as life-threatening or fatal toxicity has been reported. In a controlled clinical trial, the most common adverse events reported were diarrhea and pharyngolaryngeal pain. Rarely, myelosuppression, thrombocytopenia, and leukopenia have been reported in patients taking colchicine. Rhabdomyolysis has been occasionally observed, especially when colchicine is prescribed in combination with other drugs known to cause this effect. Monitoring is recommended under these conditions.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

You may also report negative side effects to the manufacturer of COLCRYS by calling 1-888-351-3786. Please see www.COLCRYS.com for full prescribing information.

About URL Pharma

URL Pharma, Inc., headquartered in Philadelphia, PA, is a leading specialty pharmaceutical company with fully integrated technology development, product development, manufacturing, and commercialization capabilities. After a long history of generic pharmaceutical research, development, and manufacturing, the Company has successfully transitioned to a technology-driven, specialty pharmaceutical business. The Company seeks to develop and commercialize scientifically and medically innovative products that address unmet medical needs for improvements in safety and efficacy. For more information, visit www.urlpharma.com.

For further information, please call 215-697-1900 or e-mail us at media@urlpharma.com.

SOURCE URL Pharma, Inc.


'/>"/>
SOURCE URL Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. URL Pharma Launches Co-Pay Assistance Program for Colcrys(R)
2. PDI Announces New Pharmaceutical Services Business Win With a Top 5 Pharmaceutical Company
3. National Pharmaceutical Council Welcomes New Member, Otsuka America Pharmaceutical, Inc.
4. CVS/pharmacy to Provide H1N1 Vaccinations in Rhode Island by End of Week
5. Smith & Nephew Completes Acquisition of the Assets of Nucryst Pharmaceuticals Corp.
6. KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010
7. Arena Pharmaceuticals Submits New Drug Application to FDA for Lorcaserin for Weight Management
8. WuXi PharmaTech Included in the Deloitte Technology Fast 500 Asia Pacific 2009 List for the Sixth Consecutive Year
9. PDL BioPharma Announces New Licensing Agreement With Eli Lilly
10. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
11. Raptor Pharmaceutical Corp. Announces $7.5 Million Securities Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 23, 2017 ArisGlobal, a leading ... announces agClinical 3.3, the latest version of its comprehensive ... science organizations to confidently and efficiently meet new compliance ... the electronic trial master file so that compliance is ... ...
(Date:1/23/2017)... 2017  HOPE BIOSCIENCES announced today that it ... commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) through a licensing ... nuc -Gemcitabine consists of Antisoma,s ... found on many cancer cells, and dFdCMP, an ... conjugates) or SMDCs (small molecule drug conjugates), which ...
(Date:1/23/2017)... 23, 2017  Therabron Therapeutics, Inc., a clinical-stage ... in respiratory care, today announced that the European ... has granted Orphan Drug Designation for Therabron,s CG367 ... Syndrome (BOS).  "We are pleased to ... to treat patients diagnosed with BOS following lung ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The TouchPoint Solution, ... who entered metrics into the product’s app. The data replicates and validates ... that within just 30 seconds of using Buzzies, people experienced a 74 percent ...
(Date:1/24/2017)... Michigan (PRWEB) , ... January 24, 2017 , ... The ... other advocates for drug and alcohol awareness, have worked with communities to designate the ... year, observed January 23-29, 2017, the theme is “Shatter the Myths.” As a ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... localization services for life science companies, has achieved ISO 17100:2015 certification following ... America. ISO 17100 is the globally recognized standard that establishes guidance for ...
(Date:1/23/2017)... ... 23, 2017 , ... The iaedp Foundation, recognized for its ... who treat the full spectrum of eating disorder problems, proudly announces the addition ... of the leading eating disorder treatments centers located throughout the U.S. As partners ...
(Date:1/23/2017)... ... 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy ... of making new water infrastructure a number one priority. “As we usher in a ... infrastructure to become a top priority of our new political change agents.” Kleyne pointed ...
Breaking Medicine News(10 mins):